Conditions
Advanced Solid Neoplasms
Study Overview
This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).
NATIONAL TRIAL REFERENCE NUMBER
NCT03742895
When you talk with your doctor or clinical team member, please have the national trial reference number available.
Resources
Patient Participation
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Age Range
18+
Sex
All
Study Details
This is an open label study, which means both you and the study doctor will know what you are getting. All patients who enroll in the trial will receive medication while on the study.*
100% will receive olaparib
*Patients must be centrally confirmed as HRR mutated, HRD positive, or BRCA mutated and meet all other I/E criteria to enroll in the trial.
Trial Phase
Trial Phase 2
In Phase 2 trials, researchers try to find out if a treatment works in about 100 to 500 participants – usually people who have the health condition the treatment is intended to treat. In vaccine trials, the participants are usually healthy. Phase 2 trials may happen in a doctor’s office, a clinic, or a hospital.
Start Date
End Date
- Actual study start date 12-12-2018
- Estimated primary completion date 06-30-2026
- Estimated study completion date 06-30-2026
Trial Locations
Sorry, there are no locations found.
What can you do next?
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.